Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARiTA
DRKS00008900Phase 2Completed
- Sponsor
- University of Freiburg
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cytarabine, busulfan and thiotepa in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL), sponsored by University of Freiburg. Started Feb 2016; status: completed.
02
Drugs
rituximabmethotrexatecytarabinebusulfanthiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on DRKS00008900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00008900.